News About: R&D
ViroMed to go global
ViroMed Co. plans to enter into a technology transfer or licensing transaction with respect to VM202, one of the plasmid-based therapeutics for the prevention and treatment of cardiovascular disease.
In the recent...
Bukwang announces effectiveness of Adipocell in IFATS 2008
Bukwang said that Adipocell (allogenic adipose-derived stem cell) injection, which was developed by Anterogen, its affiliate company, is clinically effective in areas such as tissue repair and wound healing in Phase I...
Ilyang gets nod for ilaprazole in KoreaIlyang Pharmaceutical Co., Ltd., announced on October 28 that they received marketing approval from the Korean Food and Drug Administration (KFDA) for ilaprazole a new investiga...
|
Daewoong to conduct phase I trial for investigational neuropathic pain product
Daewoong Pharm says it will conduct a phase I study for its investigational neuropathic pain product (DWP05195) after approval from the Korea Food and Drug Administration.
According to the company, the phase I stud...
New antibody developed to fight pancreatic cancer
The Ministry of Education, Science and Technology announced on October 28 that Korean scientists have developed a novel antibody that may repress PAUF protein linked to metastasis of pancreatic cancer, opening new pos...
Health insurance to cover more medical fees for serious illnesses
National health insurance will cover the additional medical fees in patients who pay more than one million won for six months from two million won, due to government measures expanding national health insurance covera...
Chong Kun Dang announces launching of Generic Evista tablets
Chong Kun Dang Pharmaceutical Co. announced on October 23 that the company will market its generic version of Lilly's osteoporosis treatment (raloxifene hydrochloride) in the middle of next month.
“Our launching sche...
Binex to launch immunotherapy product next year
Binex plans to commercialize its immunotherapy product for treatment of colorectal cancer in the latter half of next year.
"Our immunotherapy product is currently undergoing review by the Korean FDA for colorectal ...
Kwangdong to introduce new nucleoside analog RP101
Kwangdong Pharm says it has entered into an exclusive license with Germany based with respect to its lead drug candidate, RP101, for the treatment of pancreatic cancer.
The company will launch in RP101 in Korea in ...
Supreme Court upholds patent ruling against French drugmaker
The Supreme Court dismissed claims brought by French drugmaker Sanofi-Aventis SA in a patent lawsuit against Boryung Pharmaceutical Co. over its treatment for colorectal cancer, according to Boryung on October 15.
...
